KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) EBT (2018 - 2025)

Historic EBT for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $28.9 million.

  • BioNTech SE's EBT fell 8343.22% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$573.6 million, marking a year-over-year decrease of 6853.11%. This contributed to the annual value of -$724.2 million for FY2024, which is 15674.68% down from last year.
  • Latest data reveals that BioNTech SE reported EBT of $28.9 million as of Q3 2025, which was down 8343.22% from -$455.8 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBT registered a high of $5.6 billion during Q1 2022, and its lowest value of -$867.8 million during Q2 2024.
  • In the last 5 years, BioNTech SE's EBT had a median value of $713.6 million in 2023 and averaged $1.6 billion.
  • Per our database at Business Quant, BioNTech SE's EBT surged by 219983680252.17% in 2021 and then crashed by 14745.3% in 2024.
  • Over the past 5 years, BioNTech SE's EBT (Quarter) stood at $5.4 billion in 2021, then plummeted by 39.98% to $3.2 billion in 2022, then tumbled by 77.95% to $713.6 million in 2023, then tumbled by 54.89% to $321.9 million in 2024, then plummeted by 91.03% to $28.9 million in 2025.
  • Its EBT was $28.9 million in Q3 2025, compared to -$455.8 million in Q2 2025 and -$468.5 million in Q1 2025.